Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor

Published:2019-10-01 Issue:10 Volume:23 Page:486-495
ISSN:1557-8100
Container-title:OMICS: A Journal of Integrative Biology
language:en
Short-container-title:OMICS: A Journal of Integrative Biology

Author:

Dalva-Aydemir Sevim¹,Akyerli Cemaliye Boylu²,Yüksel Şirin Kılıçturgay¹³,Keskin Hilal¹,Yakıcıer Mustafa Cengiz³

Affiliation:

1. Biochemistry and Molecular Biology PhD Program, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.

2. Medical Biology, School of Medicine, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.

3. Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine,Biochemistry,Biotechnology

Link

https://www.liebertpub.com/doi/pdf/10.1089/omi.2019.0050

Reference66 articles.

1. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

2. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model

3. Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 and Other DNA and RNA Viruses with Diverse Genomes and Life Cycles;Microbiology Spectrum;2023-02-14

2. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin;Seminars in Cancer Biology;2022-02

3. The Contribution of Epigenetics to Cancer Immunotherapy;Trends in Immunology;2020-08

4. FOXM1: a potential therapeutic target in human solid cancers;Expert Opinion on Therapeutic Targets;2020-02-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3